EXENS — Exosens SAS Income Statement
0.000.00%
- €1.76tn
- €1.76tn
- €394.10m
Annual income statement for Exosens SAS, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 150 | 166 | 201 | 292 | 394 |
Cost of Revenue | |||||
Gross Profit | 114 | 123 | 145 | 216 | 291 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 120 | 281 | 173 | 244 | 321 |
Operating Profit | 30 | -114 | 27.8 | 48.3 | 73 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.2 | -150 | 17.1 | 20.2 | 41.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -15.8 | -149 | 11.2 | 18.4 | 30.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -15.8 | -149 | 11.2 | 18.4 | 30.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -15.8 | -149 | 11.2 | 18.4 | 30.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.153 | -0.429 | 0.011 | 0.386 | 0.605 |
Dividends per Share |